Will CETP inhibition survive the demise of torcetrapib?
Olsson
Anders G
AG
Faculty of Health Sciences, Linköping University; and Stockholm Heart Center, Bergviksvägen 48, SE-167 63 Bromma, Sweden. andol@imv.liu.se
D050197:Atherosclerosis / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D017211:Treatment Failure
D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D011804:Quinolines; C483909:torcetrapib